Guidelines for Use of Biological Agents in Psoriasis: Commonalities and Differences/Psoriasiste Biyolojik Ajan Kullanim Kilavuzlari: Ortak Noktalar Ve Farkliliklar (Continuing Medical Education/Surekli Egitim) (Report)

Guidelines for Use of Biological Agents in Psoriasis: Commonalities and Differences/Psoriasiste Biyolojik Ajan Kullanim Kilavuzlari: Ortak Noktalar Ve Farkliliklar (Continuing Medical Education/Surekli Egitim) (Report)

Giris Psoriasis, etyolojisinde genetik ve cevresel etmenlerin rol oynadigi, kronik, inflamatuvar immun aracili bir hastalik olup, ulkeden ulkeye ve irklara gore prevalansi %0.5-4.6 arasinda degismektedir (1). Onceleri sadece deriyi ve eklemleri ilgilendiren bir hastalik olarak dusunulurken, son zamanlarda yapilan calismalar isiginda gunumuzde artik, immun aracili ve kardiyovaskuler hastaliklar ile lenfoma ve deri kanserleri gibi onemli […]

Since the Previous CME on Lipidology was Published in 2003 There have been Many New and Exciting Developments in Lipid-Modifying Therapy (New Therapeutic Developments in Lipidology) (Continuing Medical Education) (Report)

Since the Previous CME on Lipidology was Published in 2003 There have been Many New and Exciting Developments in Lipid-Modifying Therapy (New Therapeutic Developments in Lipidology) (Continuing Medical Education) (Report)

At the time of writing there are some new lipid-lowering drugs on the market, but attempts to influence atherosclerosis by new mechanisms have unfortunately generally been unsuccessful so far. This article briefly reviews selected developments that may be of interest to the non-specialist practitioner.

Biologic Agents in Psoriasis/Psoriasiste Biyolojik Ajanlar (Continuing Medical Education/Surekli Egitim) (Report)

Biologic Agents in Psoriasis/Psoriasiste Biyolojik Ajanlar (Continuing Medical Education/Surekli Egitim) (Report)

Giris Son yillarda psoriazis immunopatogenezine ait bilgilerin cogalmasi ile bu hastaliga ozgu ve yan etkiler acisindan daha guvenli tedavilerin gelistirilmesine yonelik calismalar da ivme kazanmistir. Genetik muhendisligini kullanan biyoteknolojik yontemler guvenli ve etkin bir tedavi icin gerekli altyapi ve firsati dogurmus; ortaya cikan rekombinan proteinler biyolojik tedavinin temellerini olusturmustur.

Psoriasis, Introduction, General Information, Epidemiology/Psoriasis, Genel Bilgiler, Epidemiyoloji (Continuing Medical Education/Surekli Egitim) (Disease/Disorder Overview)

Psoriasis, Introduction, General Information, Epidemiology/Psoriasis, Genel Bilgiler, Epidemiyoloji (Continuing Medical Education/Surekli Egitim) (Disease/Disorder Overview)

Giris Psoriasis, keskin sinirli, eritemli plak veya papuller uzerinde yerlesmis parlak, sedefi-beyaz skuamlarla karakterize, kronik seyirli, inflamatuvar bir hastaliktir (1). Skuamlarin renginden dolayi halk arasinda “Sedef Hastaligi” olarak bilinmektedir. Hastalik siklikla sacli deri, diz, dirsek, sakral bolge ve eklemlerin ekstensor yuzlerinde simetrik olarak yerlesen lezyonlarla seyretmektedir (2). Hastaligin etyopatogenezinde immunolojik, otoimmun ve genetik faktorlerin etkili […]

Psoriasis and Co-Morbidities/Psoriasis Ve Komorbiditeler (Continuing Medical Education/Surekli Egitim) (Report)

Psoriasis and Co-Morbidities/Psoriasis Ve Komorbiditeler (Continuing Medical Education/Surekli Egitim) (Report)

Giris Psoriasis genel populasyonda %1-3 oraninda gorulen ve immun aracili mekanizmalarla gelistigi icin Immune Mediated Inflammatory Disease (IMID) olarak tanimlanan kronik inflamatuvar hastaliklardan biridir. Bu gruptaki diger hastaliklar arasinda ulseratif kolit, Crohn hastaligi gibi gastraointestinal sistem hastaliklari, psoriatik artrit, romatoid artrit ve ankilozan spondilit gibi romatolojik hastaliklar bulunmaktadir. Psoriasis IMID grubu hastaliklar icinde en sik […]